SOLID COMPOSITION COMPRISING SOLUBILISED BRADYKININ B2-RECEPTOR ANTAGONISTS

The invention relates to solid dispersions for oral administration comprising a bradykinin B2 receptor antagonist having a chemical structure according to Formula (1), or a salt or solvate thereof, wherein R is deuterium or hydrogen: Formula (1) such as (S)-./V-(l-deutero-l-(3-chloro-5-fluoro-2-((2-methyl-4-(l-methyl-l/f-l,2,4-triazol-5- yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide. The solid dispersions comprise the BK B2 receptor antagonist in the amorphous form and homogeneously dispersed in a pharmaceutically acceptable polymer. Furthermore, methods for preparation and uses of the solid dispersions, including therapeutic uses, are provided.